Recently Added Drugs
1. Aristada patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12629366 | ALKERMES | Pharmaceutical Compositions Comprising Sorbitan Esters |
Dec, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 05, 2020 |
Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient
NCE-1 date: 06 October, 2019
Market Authorisation Date: 05 October, 2015
Treatment: Treatment of schizophrenia
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
ARISTADA family patents
2. Auvelity patent expiration
AUVELITY's oppositions filed in EPO
Can you believe AUVELITY received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10064857 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(8 years from now) | |
| US10092561 | AXSOME | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Nov, 2034
(8 years from now) | |
| US10463634 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(8 years from now) | |
| US10512643 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(8 years from now) | |
| US10881624 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(8 years from now) | |
| US9278095 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 18, 2025 |
| New Indication(I-913) | Apr 30, 2029 |
Drugs and Companies using BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE ingredient
Market Authorisation Date: 30 April, 2026
Treatment: The treatment of agitation associated with dementia due to alzheimer’s disease by increasing dextromethorphan plasma levels in extensive metabolizers of dextromethorphan
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of AUVELITY before its drug patent expiration?
More Information on Dosage
AUVELITY family patents
3. Belsomra patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12599610 | MERCK | Solid Dosage Formulations Of An Orexin Receptor Antagonist |
May, 2033
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 13, 2019 |
| M(M-253) | Jan 29, 2023 |
Drugs and Companies using SUVOREXANT ingredient
NCE-1 date: 13 August, 2018
Market Authorisation Date: 13 August, 2014
Treatment: NA
Dosage: TABLET
How can I launch a generic of BELSOMRA before its drug patent expiration?
More Information on Dosage
BELSOMRA family patents
4. Cavhanza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11389450 | FLEX | Amorphous Nilotinib Microparticles And Uses Thereof |
Jan, 2041
(14 years from now) | |
| US12016861 | FLEX | Amorphous Nilotinib Microparticles And Uses Thereof |
Jan, 2041
(14 years from now) | |
| US12029740 | FLEX | Amorphous Nilotinib Microparticles And Uses Thereof |
Jan, 2041
(14 years from now) | |
| US11559485 | FLEX | Orally Disintegrating Tablet Comprising Amorphous Solid Dispersion Of Nilotinib |
Apr, 2041
(14 years from now) | |
Drugs and Companies using NILOTINIB ingredient
Market Authorisation Date: 29 May, 2026
Treatment: Use of nilotinib for treatment of adult patients with chronic phase and accelerated phase ph+ chronic myeloid leukemia resistant to or intolerant to prior therapy that included imatinib, when administ...
Dosage: TABLET, ORALLY DISINTEGRATING
More Information on Dosage
CAVHANZA family patents
5. Cuvrior patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12662445 | ORPHALAN | NA |
May, 2039
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 28, 2025 |
| Orphan Drug Exclusivity(ODE-401) | Apr 28, 2029 |
Drugs and Companies using TRIENTINE TETRAHYDROCHLORIDE ingredient
Market Authorisation Date: 28 April, 2022
Treatment: A method for the treatment of adult patients with stable wilson's disease who are de-coppered and tolerant to penicillamine
Dosage: TABLET
How can I launch a generic of CUVRIOR before its drug patent expiration?
More Information on Dosage
CUVRIOR family patents
6. Descovy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12661323 | GILEAD | NA |
Jun, 2036
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 28, 2020 |
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
| New Indication(I-812) | Oct 03, 2022 |
| Orphan Drug Exclusivity(ODE-284) | Sep 28, 2024 |
| Orphan Drug Exclusivity(ODE-285) | Sep 28, 2024 |
| M(M-316) | Jun 20, 2028 |
| Orphan Drug Exclusivity(ODE-457) | Jan 07, 2029 |
Drugs and Companies using EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient
NCE-1 date: 06 November, 2019
Market Authorisation Date: 07 January, 2022
Treatment: NA
Dosage: TABLET
How can I launch a generic of DESCOVY before its drug patent expiration?
More Information on Dosage
DESCOVY family patents
7. Fanapt patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10570453 | VANDA | Method Of Predicting A Predisposition To Qt Prolongation |
Mar, 2028
(1 year, 8 months from now) | |
| US10563259 | VANDA | Method Of Treatment Based On Polymorphisms Of The Kcnq1 Gene |
Jul, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 06, 2014 |
| M(M-180) | May 26, 2019 |
| New Indication(I-939) | Apr 02, 2027 |
Drugs and Companies using ILOPERIDONE ingredient
NCE-1 date: 06 May, 2013
Market Authorisation Date: 06 May, 2009
Treatment: Method for acute treatment of manic or mixed episodes associated with bipolar i disorder in adults by administering iloperidone to a patient by lowering the dose after determining that the patient has...
Dosage: TABLET
How can I launch a generic of FANAPT before its drug patent expiration?
More Information on Dosage
FANAPT family patents
8. Gomekli patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12661330 | SPRINGWORKS | NA |
Feb, 2044
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 11, 2030 |
| Orphan Drug Exclusivity(ODE-488) | Feb 11, 2032 |
Drugs and Companies using MIRDAMETINIB ingredient
NCE-1 date: 11 February, 2029
Market Authorisation Date: 11 February, 2025
Treatment: Treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (nf1) who have symptomatic plexiform neurofibromas (pn) not amenable to complete resection
Dosage: CAPSULE
More Information on Dosage
GOMEKLI family patents
9. Hemiclor patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12667554 | PRM | NA |
Sep, 2045
(19 years from now) | |
Drugs and Companies using CHLORTHALIDONE ingredient
Market Authorisation Date: 17 March, 2025
Treatment: NA
Dosage: TABLET
More Information on Dosage
HEMICLOR family patents
10. Inlexzo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12636300 | JANSSEN | Methods Of Treatment And Maintenance Therapy For Bladder Cancer Using Gemcitabine |
Nov, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 09, 2028 |
Drugs and Companies using GEMCITABINE HYDROCHLORIDE ingredient
Market Authorisation Date: 09 September, 2025
Treatment: Treatment of bcg-unresponsive, non-muscle invasive bladder cancer by intravesical administration of eq. 225 mg gemcitibine every 3 weeks for 6 months followed by every 12 weeks for up to 18 months
Dosage: SYSTEM
More Information on Dosage
INLEXZO family patents
11. Jakafi Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7598257 (Pediatric) | INCYTE | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
Jun, 2028
(1 year, 11 months from now) | |
|
US8415362 (Pediatric) | INCYTE | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
Jun, 2028
(1 year, 11 months from now) | |
|
US10016429 (Pediatric) | INCYTE | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(2 years from now) | |
|
US11213528 (Pediatric) | INCYTE | Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile |
Dec, 2028
(2 years from now) | |
|
US8722693 (Pediatric) | INCYTE | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(2 years from now) | |
|
US8822481 (Pediatric) | INCYTE | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(2 years from now) | |
|
US8829013 (Pediatric) | INCYTE | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(2 years from now) | |
|
US10874616 (Pediatric) | INCYTE | Sustained-Release Dosage Forms Of Ruxolitinib |
May, 2034
(7 years from now) | |
|
US11576864 (Pediatric) | INCYTE | Sustained-Release Dosage Forms Of Ruxolitinib |
May, 2034
(7 years from now) | |
|
US11576865 (Pediatric) | INCYTE | Sustained-Release Dosage Forms Of Ruxolitinib |
May, 2034
(7 years from now) | |
|
US11896717 (Pediatric) | INCYTE | Sustained-Release Dosage Forms Of Ruxolitinib |
May, 2034
(7 years from now) | |
|
US11337927 (Pediatric) | INCYTE | Sustained-Release Dosage Forms Of Ruxolitinib |
Jul, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| ODE*(ODE*) | Sep 22, 2028 |
| Pediatric Exclusivity(PED) | Mar 22, 2029 |
Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient
Market Authorisation Date: 01 May, 2026
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
JAKAFI XR family patents
12. Kyprolis patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12636340 | ONYX AMGEN | Methods Of Treating Multiple Myeloma |
Apr, 2041
(14 years from now) | |
|
US12636340 (Pediatric) | ONYX AMGEN | Methods Of Treating Multiple Myeloma |
Oct, 2041
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2017 |
| New Indication(I-712) | Jul 24, 2018 |
| New Indication(I-722) | Jan 21, 2019 |
| New Indication(I-723) | Jan 21, 2019 |
| Orphan Drug Exclusivity(ODE) | Jul 20, 2019 |
| Orphan Drug Exclusivity(ODE-27) | Jul 20, 2019 |
| New Dosing Schedule(D-172) | Sep 28, 2021 |
| New Indication(I-842) | Aug 20, 2023 |
| M(M-14) | May 22, 2028 |
| Pediatric Exclusivity(PED) | Nov 22, 2028 |
Drugs and Companies using CARFILZOMIB ingredient
NCE-1 date: 20 July, 2016
Market Authorisation Date: 07 June, 2018
Treatment: Treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with daratumumab and dexamethasone
Dosage: POWDER
How can I launch a generic of KYPROLIS before its drug patent expiration?
More Information on Dosage
KYPROLIS family patents
13. Levothyroxine Sodium patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12636270 | FRESENIUS KABI | Levothyroxine Liquid Formulations |
Dec, 2036
(10 years from now) | |
Drugs and Companies using LEVOTHYROXINE SODIUM ingredient
Market Authorisation Date: 11 April, 2019
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of LEVOTHYROXINE SODIUM before its drug patent expiration?
More Information on Dosage
LEVOTHYROXINE SODIUM family patents
14. Nouress patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12569514 | BAXTER | NA |
Jan, 2039
(12 years from now) | |
Drugs and Companies using CYSTEINE HYDROCHLORIDE ingredient
Market Authorisation Date: 13 December, 2019
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
NOURESS family patents
15. Orladeyo patent expiration
Can you believe ORLADEYO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10329260 (Pediatric) | BIOCRYST | Human Plasma Kallikrein Inhibitors |
Sep, 2035
(9 years from now) | |
|
US10689346 (Pediatric) | BIOCRYST | Human Plasma Kallikrein Inhibitors |
Sep, 2035
(9 years from now) | |
|
US11230530 (Pediatric) | BIOCRYST | Human Plasma Kallikrein Inhibitors |
Sep, 2035
(9 years from now) | |
|
US11708333 (Pediatric) | BIOCRYST | Human Plasma Kallikrein Inhibitors |
Sep, 2035
(9 years from now) | |
|
US12116346 (Pediatric) | BIOCRYST | Human Plasma Kallikrein Inhibitors |
Sep, 2035
(9 years from now) | |
|
US10125102 (Pediatric) | BIOCRYST | Human Plasma Kallikrein Inhibitors |
Oct, 2035
(9 years from now) | |
|
US10662160 (Pediatric) | BIOCRYST | NA |
May, 2040
(13 years from now) | |
|
US11117867 (Pediatric) | BIOCRYST | Crystalline Salts Of A Plasma Kallikrein Inhibitor |
May, 2040
(13 years from now) | |
|
US11618733 (Pediatric) | BIOCRYST | Crystalline Salts Of A Plasma Kallikrein Inhibitor |
May, 2040
(13 years from now) | |
|
US12344585 (Pediatric) | BIOCRYST | Crystalline Salts Of A Plasma Kallikrein Inhibitor |
May, 2040
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 03, 2025 |
| Orphan Drug Exclusivity(ODE-333) | Dec 03, 2027 |
| Pediatric Exclusivity(PED) | Jun 11, 2029 |
| New Product(NP) | Dec 11, 2028 |
Drugs and Companies using BEROTRALSTAT DIHYDROCHLORIDE ingredient
Market Authorisation Date: 11 December, 2025
Treatment: NA
Dosage: PELLETS
How can I launch a generic of ORLADEYO before its drug patent expiration?
More Information on Dosage
ORLADEYO family patents
16. Ozempic patent expiration
What is Ozempic?
Ozempic (semaglutide) is an injectable medication used to improve blood sugar levels in adults with type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists and works by mimicking the effects of the hormone GLP-1, which helps regulate blood sugar levels. Ozempic slows digestion and decreases appetite, leading to improved glycemic control and potential weight loss benefits.
What is the Ozempic controversy?
The injectable diabetes medication Ozempic (semaglutide) has recently seen its FDA-approved label updated to warn of potential serious intestinal side effects like obstruction or blockage. The newly added FDA warning highlights that Ozempic may cause severe gastrointestinal issues like intestinal obstruction, intense abdominal pain, vomiting, constipation, and abdominal swelling.
OZEMPIC's oppositions filed in EPO
OZEMPIC IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8129343 | NOVO NORDISK | Acylated GLP-1 compounds |
Dec, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10335462 | NOVO NORDISK | Use of long-acting GLP-1 peptides |
Jun, 2033
(6 years from now) | |
| US12569543 | NOVO NORDISK | Semaglutide In Cardiovascular Conditions |
Apr, 2037
(10 years from now) | |
| US10888605 | NOVO NORDISK | GLP-1 compositions and uses thereof |
Aug, 2038
(12 years from now) | |
| US11752198 | NOVO NORDISK | GLP-1 compositions and uses thereof |
Aug, 2038
(12 years from now) | |
| US12214017 | NOVO NORDISK | GLP-1 compositions and uses thereof |
Aug, 2038
(12 years from now) | |
| US12295988 | NOVO NORDISK | Semaglutide in medical therapy |
Oct, 2038
(12 years from now) | |
| US11318191 | NOVO NORDISK | GLP-1 compositions and uses thereof |
Feb, 2041
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| New Indication(I-822) | Jan 16, 2023 |
| New Dosing Schedule(D-185) | Mar 28, 2025 |
| New Indication(I-961) | Jan 28, 2028 |
| New Indication(I-976) | Oct 17, 2028 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 05 May, 2026
Treatment: Method of treating type 2 diabetes; Reduction of the risk of major adverse cardiovascular events in subjects with type 2 diabetes mellitus and cardiovascular disease; Reduction of the risk of major ca...
Dosage: SOLUTION
How can I launch a generic of OZEMPIC before its drug patent expiration?
More Information on Dosage
OZEMPIC family patents
17. Subvenite patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12629377 | OWP | Lamotrigine Oral Liquid Suspension And Use Thereof |
May, 2040
(13 years from now) | |
| US12636289 | OWP | Lamotrigine Oral Liquid Suspension And Use Thereof |
May, 2040
(13 years from now) | |
Drugs and Companies using LAMOTRIGINE ingredient
Market Authorisation Date: 16 September, 2025
Treatment: Maintenance treatment of bipolar i disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy
Dosage: SUSPENSION
More Information on Dosage
SUBVENITE family patents
18. Trimbow patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10159645 | CHIESI | Combination Therapy For Copd |
Dec, 2030
(4 years from now) | |
| US10806701 | CHIESI | Aerosol Formulation For Copd |
Dec, 2030
(4 years from now) | |
| US11389401 | CHIESI | Combination Therapy For Copd |
Dec, 2030
(4 years from now) | |
| US11590074 | CHIESI | Aerosol Formulation For Copd |
Dec, 2030
(4 years from now) | |
| US12357568 | CHIESI | Aerosol Formulation For Copd |
Dec, 2030
(4 years from now) | |
| US10617638 | CHIESI | Stable Pressurized Aerosol Solution Composition Of Glycopyrronium Bromide And Formoterol Combination |
Dec, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 14, 2029 |
Market Authorisation Date: 14 May, 2026
Treatment: Maintenance treatment of asthma
Dosage: AEROSOL, METERED
More Information on Dosage
TRIMBOW family patents
19. Truqap patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11236095 | ASTRAZENECA | Protein Kinase B Inhibitors |
Oct, 2028
(2 years from now) | |
| US9492453 | ASTRAZENECA | Protein Kinase B Inhibitors |
Oct, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 16, 2028 |
| New Indication(I-991) | Jun 12, 2029 |
Drugs and Companies using CAPIVASERTIB ingredient
NCE-1 date: 17 November, 2027
Market Authorisation Date: 16 November, 2023
Treatment: Treatment in combination with abiraterone and prednisone of metastatic androgen pathway modulation-naive or -sensitive (mapmn/s) prostate cancer that is pten-deficient
Dosage: TABLET
More Information on Dosage
TRUQAP family patents
20. Tyrvaya patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12653824 | OYSTER POINT | Compositions And Use Of Varenicline For Treating Dry Eye |
Oct, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 15, 2024 |
Drugs and Companies using VARENICLINE TARTRATE ingredient
Market Authorisation Date: 15 October, 2021
Treatment: NA
Dosage: SPRAY
How can I launch a generic of TYRVAYA before its drug patent expiration?
More Information on Dosage
TYRVAYA family patents
21. Upneeq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12648930 | RVL | Compositions And Methods For Treating Ocular Disorders |
Dec, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 08, 2023 |
Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 08 July, 2020
Treatment: Method of treating blepharoptosis
Dosage: SOLUTION/DROPS
More Information on Dosage
UPNEEQ family patents
22. Uptravi patent expiration
UPTRAVI's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7205302 | ACTELION | Heterocyclic compound derivatives and medicines |
Oct, 2026
(3 months from now) | |
| US8791122 | ACTELION | Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and method for producing the same |
Aug, 2030
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7205302 (Pediatric) | ACTELION | Heterocyclic Compound Derivatives And Medicines |
Apr, 2027
(9 months from now) | |
| US9173881 | ACTELION | Therapeutic compositions containing macitentan |
Aug, 2029
(3 years from now) | |
|
US9173881 (Pediatric) | ACTELION | Therapeutic Compositions Containing Macitentan |
Feb, 2030
(3 years from now) | |
| US9284280 | ACTELION | Use of form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide |
Jun, 2030
(3 years from now) | |
|
US9284280 (Pediatric) | ACTELION | Use Of Form-I Crystal Of 2-{4-[N-(5,6-Diphenylpyrazin-2-Yl)-N-Isopropylamino]Butyloxy}-N-(Methylsulfonyl)Acetamide |
Dec, 2030
(4 years from now) | |
|
US8791122 (Pediatric) | ACTELION | Form-I Crystal Of 2-{4-[N-(5,6-Diphenylpyrazin-2-Yl)-N-Isopropylamino]Butyloxy}-N-(Methylsulfonyl)Acetamide And Method For Producing The Same |
Feb, 2031
(4 years from now) | |
| US10821108 | ACTELION | Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide |
Dec, 2036
(10 years from now) | |
| US10828298 | ACTELION | Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy]-N-(methylsulfonyl)acetamide |
Dec, 2036
(10 years from now) | |
|
US10821108 (Pediatric) | ACTELION | Pharmaceutical Composition Containing 2-{4-[N-(5,6-Diphenylpyrazin-2-Yl)-N-Isopropylamino]Butyloxy}-N-(Methylsulfonyl)Acetamide |
Jun, 2037
(10 years from now) | |
|
US10828298 (Pediatric) | ACTELION | Pharmaceutical Composition Containing 2-{4-[N-(5,6-Diphenylpyrazin-2-Yl)-N-Isopropylamino]Butyloxy]-N-(Methylsulfonyl)Acetamide |
Jun, 2037
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 21, 2020 |
| Orphan Drug Exclusivity(ODE) | Dec 21, 2022 |
| Orphan Drug Exclusivity(ODE-106) | Dec 21, 2022 |
| New Patient Population(NPP) | May 23, 2029 |
| New Strength(NS) | May 23, 2029 |
| Pediatric Exclusivity(PED) | Nov 23, 2029 |
Drugs and Companies using SELEXIPAG ingredient
NCE-1 date: 22 December, 2019
Market Authorisation Date: 23 May, 2026
Treatment: Method of treating pulmonary arterial hypertension comprising administering selexipag in combination with the endothelin receptor antagonist macitentan; Method of treating pulmonary arterial hypertens...
Dosage: TABLET
How can I launch a generic of UPTRAVI before its drug patent expiration?
More Information on Dosage
UPTRAVI family patents
23. Wainua patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9127276 | ASTRAZENECA | Conjugated antisense compounds and their use |
May, 2034
(7 years from now) | |
| US9181549 | ASTRAZENECA | Conjugated antisense compounds and their use |
May, 2034
(7 years from now) | |
| US10683499 | ASTRAZENECA | Compositions and methods for modulating TTR expression |
Aug, 2034
(8 years from now) | |
Drugs and Companies using EPLONTERSEN SODIUM ingredient
NCE-1 date: 22 December, 2027
Market Authorisation Date: 15 April, 2026
Treatment: Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis
Dosage: SOLUTION
More Information on Dosage
WAINUA family patents
24. Wegovy patent expiration
WEGOVY's oppositions filed in EPO
WEGOVY IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8129343 | NOVO NORDISK | Acylated GLP-1 compounds |
Dec, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9764003 | NOVO NORDISK | Use of long-acting GLP-1 peptides |
Jun, 2033
(6 years from now) | |
| US12569543 | NOVO NORDISK | Semaglutide In Cardiovascular Conditions |
Apr, 2037
(10 years from now) | |
| US10888605 | NOVO NORDISK | GLP-1 compositions and uses thereof |
Aug, 2038
(12 years from now) | |
| US11752198 | NOVO NORDISK | GLP-1 compositions and uses thereof |
Aug, 2038
(12 years from now) | |
| US12214017 | NOVO NORDISK | GLP-1 compositions and uses thereof |
Aug, 2038
(12 years from now) | |
| US12029779 | NOVO NORDISK | Semaglutide in medical therapy |
Oct, 2038
(12 years from now) | |
| US12551536 | NOVO NORDISK | Semaglutide In Medical Therapy |
Oct, 2038
(12 years from now) | |
| US11478533 | NOVO NORDISK | Semaglutide For Use In Medicine |
May, 2040
(13 years from now) | |
| US11318191 | NOVO NORDISK | GLP-1 compositions and uses thereof |
Feb, 2041
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| New Product(NP) | Dec 22, 2028 |
| New Patient Population(NPP) | Dec 23, 2025 |
| New Dosing Schedule(D-190) | Jul 21, 2026 |
| New Indication(I-935) | Mar 08, 2027 |
| New Indication(I-973) | Aug 15, 2028 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 04 June, 2021
Treatment: Method for weight management according to a dose escalation schedule; Reduction of the risk of major cardiovascular events in subjects with cardiovascular disease and either obesity or overweight; Met...
Dosage: SOLUTION
How can I launch a generic of WEGOVY before its drug patent expiration?
More Information on Dosage
WEGOVY family patents
25. Widaplik patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12673047 | AZURITY | NA |
Jan, 2038
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 05, 2028 |
Drugs and Companies using AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN ingredient
Market Authorisation Date: 05 June, 2025
Treatment: NA
Dosage: TABLET
More Information on Dosage
WIDAPLIK family patents
26. Xocova patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9150546 | SHIONOGI | Triazine Derivative And Pharmaceutical Composition Comprising The Same |
Dec, 2030
(4 years from now) | |
| US11814368 | SHIONOGI | Triazine Derivatives Having Virus Replication Inhibitory Activity And Pharmaceutical Composition Comprising The Same |
May, 2042
(15 years from now) | |
| US12559474 | SHIONOGI | Triazine Derivatives Having Virus Replication Inhibitory Activity And Pharmaceutical Composition Comprising The Same |
May, 2042
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 29, 2031 |
Drugs and Companies using ENSITRELVIR ingredient
NCE-1 date: 29 May, 2030
Market Authorisation Date: 29 May, 2026
Treatment: Post-exposure prophylaxis of coronavirus disease 2019 (covid 19) in adults and adolescents 12 years of age and older
Dosage: TABLET
More Information on Dosage
XOCOVA family patents
27. Zaynich patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8822450 | WOCKHARDT | 1,6-Diazabicyclo [3,2,1] Octan-7-One Derivatives And Their Use In The Treatment Of Bacterial Infections |
Aug, 2032
(6 years from now) | |
| US8853197 | WOCKHARDT | NA |
Aug, 2032
(6 years from now) | |
| US9657021 | WOCKHARDT | Process For Preparation Of (2S, 5R)-7-Oxo-6-Sulphooxy-2[((3R)-Piperidine-3-Carbonyl)-Hydrazino Carbonyl]-1,6-Diaza-Bicyclo [3.2.1]-Octane |
Oct, 2033
(7 years from now) | |
| US9834557 | WOCKHARDT | Process For Preparation Of (2S, 5R)-7-Oxo-6-Sulphooxy-2-[((3R)-Piperidine-3-Carbonyl)-Hydrazino Carbonyl]-1,6-Diaza-Bicyclo [3.2.1]-Octane |
Oct, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9132133 | WOCKHARDT | Nitrogen Containing Compounds |
Aug, 2032
(6 years from now) | |
| US9381200 | WOCKHARDT | Nitrogen Containing Compounds |
Aug, 2032
(6 years from now) | |
| US9827235 | WOCKHARDT | Pharmaceutical Compositions Comprising Antibacterial Agents |
Aug, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 29, 2031 |
| Generating Antibiotic Incentives Now(GAIN) | May 29, 2036 |
Drugs and Companies using CEFEPIME HYDROCHLORIDE; ZIDEBACTAM ingredient
NCE-1 date: 29 May, 2030
Market Authorisation Date: 29 May, 2026
Treatment: Complicated urinary tract infections, including pyelonephritis
Dosage: POWDER
More Information on Dosage
ZAYNICH family patents